Stock listing
Frankfurt:NNFN MannKind Corporation Aktie
German listing (Frankfurt) of MannKind Corporation · home listing NASDAQ:MNKD
Follow MannKind Corporation into a list and get an email when it puts out news.
Share price · FWB:NNFN
€3.49 EUR -0.17 (-4.5%)
Close on Nov 20, 2026
- Day range
- €3.49 – €3.49 EURNov 20, 2026
- Market cap
- €1.12B EURAt the close on Nov 20, 2026 · price × 321.5M shares outstanding
- 52-week range
- €1.94 – €5.12 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €2,239 EURMedian day 0 shares · 41 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MNKD · Home | $3.85 USD | -0.22 (-5.4%) | 4,178,911 | $3.90 | $4.08 | $3.83 | $4.07 | Close on Nov 20, 2026 |
| Frankfurt:NNFN | €3.491 EUR | -0.166 (-4.5%) | — | €3.491 | €3.491 | €3.491 | €3.657 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:NNFN · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €2.928 | -0.493 | -14.4% | €2.928 | €2.928 | €2.928 | 0 | |
| €3.421 | +0.139 | +4.2% | €3.421 | €3.421 | €3.421 | 400 | |
| €3.282 | +0.08 | +2.5% | €3.282 | €3.282 | €3.282 | 400 | |
| €3.202 | +0.103 | +3.3% | €3.202 | €3.202 | €3.202 | 0 | |
| €3.099 | +0.009 | +0.3% | €3.099 | €3.099 | €3.099 | 0 | |
| €3.09 | +0.058 | +1.9% | €3.09 | €3.09 | €3.09 | 0 | |
| €3.032 | +0.114 | +3.9% | €3.032 | €3.032 | €3.032 | 20 | |
| €2.918 | +0.08 | +2.8% | €2.918 | €2.918 | €2.918 | 50 | |
| €2.838 | +0.011 | +0.4% | €2.838 | €2.838 | €2.838 | 0 | |
| €2.827 | +0.014 | +0.5% | €2.827 | €2.827 | €2.827 | 0 | |
| €2.813 | +0.191 | +7.3% | €2.813 | €2.813 | €2.813 | 1,424 | |
| €2.622 | -0.118 | -4.3% | €2.622 | €2.622 | €2.622 | 6,000 | |
| €2.74 | +0.043 | +1.6% | €2.74 | €2.74 | €2.74 | 0 | |
| €2.697 | -0.017 | -0.6% | €2.697 | €2.697 | €2.697 | 0 | |
| €2.714 | -0.112 | -4.0% | €2.714 | €2.714 | €2.714 | 0 | |
| €2.826 | +0.19 | +7.2% | €2.826 | €2.826 | €2.826 | 0 | |
| €2.636 | -0.051 | -1.9% | €2.636 | €2.636 | €2.636 | 0 | |
| €2.687 | -0.078 | -2.8% | €2.687 | €2.687 | €2.687 | 0 | |
| €2.765 | -0.129 | -4.5% | €2.765 | €2.765 | €2.765 | 0 | |
| €2.894 | -0.121 | -4.0% | €2.894 | €2.894 | €2.894 | 0 | |
| €3.015 | -0.059 | -1.9% | €3.015 | €3.015 | €3.015 | 5,280 | |
| €3.074 | -0.164 | -5.1% | €3.046 | €3.105 | €3.025 | 802 | |
| €3.238 | -0.126 | -3.7% | €3.238 | €3.238 | €3.238 | 0 | |
| €3.364 | +0.028 | +0.8% | €3.364 | €3.364 | €3.364 | 0 | |
| €3.336 | -0.139 | -4.0% | €3.341 | €3.341 | €3.309 | 1,500 | |
| €3.475 | +0.006 | +0.2% | €3.475 | €3.475 | €3.475 | 798 | |
| €3.469 | +0.575 | +19.9% | €3.469 | €3.469 | €3.469 | 3,000 | |
| €2.894 | -0.021 | -0.7% | €2.894 | €2.894 | €2.894 | 0 | |
| €2.915 | +0.018 | +0.6% | €2.915 | €2.915 | €2.915 | 0 | |
| €2.897 | +0.053 | +1.9% | €2.897 | €2.897 | €2.897 | 0 | |
| €2.844 | -0.078 | -2.7% | €2.844 | €2.844 | €2.844 | 200 | |
| €2.922 | -0.078 | -2.6% | €2.922 | €2.922 | €2.922 | 0 | |
| €3.00 | -0.02 | -0.7% | €3.00 | €3.00 | €3.00 | 0 | |
| €3.02 | -0.049 | -1.6% | €3.02 | €3.02 | €3.02 | 0 | |
| €3.069 | -0.07 | -2.2% | €3.069 | €3.069 | €3.069 | 0 | |
| €3.139 | +0.068 | +2.2% | €3.139 | €3.139 | €3.139 | 886 | |
| €3.071 | +0.078 | +2.6% | €3.071 | €3.071 | €3.071 | 0 | |
| €2.993 | -0.197 | -6.2% | €2.993 | €2.993 | €2.993 | 0 | |
| €3.19 | +0.058 | +1.9% | €3.19 | €3.19 | €3.19 | 0 | |
| €3.132 | -0.08 | -2.5% | €3.132 | €3.132 | €3.132 | 0 | |
| €3.212 | -0.129 | -3.9% | €3.212 | €3.212 | €3.212 | 20,000 | |
| €3.341 | -0.205 | -5.8% | €3.341 | €3.341 | €3.341 | 0 | |
| €3.546 | +0.127 | +3.7% | €3.546 | €3.546 | €3.546 | 0 | |
| €3.419 | -0.054 | -1.6% | €3.419 | €3.419 | €3.419 | 0 | |
| €3.473 | +0.092 | +2.7% | €3.473 | €3.473 | €3.473 | 0 | |
| €3.381 | -0.068 | -2.0% | €3.381 | €3.381 | €3.381 | 30 | |
| €3.449 | +0.085 | +2.5% | €3.449 | €3.449 | €3.449 | 0 | |
| €3.364 | -0.049 | -1.4% | €3.364 | €3.364 | €3.364 | 0 | |
| €3.413 | +0.072 | +2.2% | €3.413 | €3.413 | €3.413 | 0 | |
| €3.341 | -0.104 | -3.0% | €3.341 | €3.341 | €3.341 | 0 | |
| €3.445 | -0.031 | -0.9% | €3.445 | €3.445 | €3.445 | 0 | |
| €3.476 | -0.053 | -1.5% | €3.476 | €3.476 | €3.476 | 0 | |
| €3.529 | +0.075 | +2.2% | €3.529 | €3.529 | €3.529 | 0 | |
| €3.454 | -0.037 | -1.1% | €3.454 | €3.454 | €3.454 | 0 | |
| €3.491 | -0.077 | -2.2% | €3.491 | €3.491 | €3.491 | 0 | |
| €3.568 | -0.127 | -3.4% | €3.568 | €3.568 | €3.568 | 200 | |
| €3.695 | +0.24 | +6.9% | €3.695 | €3.695 | €3.695 | 0 |
Splits
1 split · FWB:NNFN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation |
- Ticker
- Frankfurt:NNFN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
MannKind to Participate in Upcoming Investor Conferences
Latest earnings call · Nov 5, 2026
MannKind (NASDAQ:MNKD) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 5, 2026
Q2 2026 Earnings Presentation
Earnings · 36 slides
Latest news
Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)
Nov 5, 2026
Closed €2.93 (-14.4%) on Nov 6, 2026
MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026
Closed €2.93 (-14.4%) on Nov 6, 2026
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
Oct 29, 2026
Closed €3.09 (+1.9%) on Oct 30, 2026
MannKind to Participate in the Chardan Healthcare Conference
Oct 14, 2026
Closed €2.64 (-1.9%) on Oct 15, 2026
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
Oct 9, 2026
Closed €3.02 (-1.9%) on Oct 9, 2026
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
Sep 9, 2026
Closed €3.55 (+3.7%) on Sep 9, 2026
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 5, 2026
Closed €3.34 (-2.1%) on Aug 6, 2026
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
Jul 29, 2026
Closed €3.35 (-2.2%) on Jul 29, 2026
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
Jul 28, 2026
Closed €3.35 (-2.2%) on Jul 29, 2026
MannKind Corporation on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 33 in the last 12 months · 208 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 21 calls with a replay · 21 with a transcript · latest Nov 5, 2026
- Decks
- 9 decks · latest Aug 5, 2026
Where MannKind Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MNKD · Home listing | NASDAQ | United States | USD |
| BOATS:MNKD | BOATS | United States | USD |
| gettex:NNFN | gettex | Germany | EUR |
| LS Exchange:A2DMZL | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2DMZL | Lang & Schwarz | Germany | EUR |
| Tradegate:NNFN | Tradegate | Germany | EUR |
| Munich:NNFN | Munich | Germany | EUR |
| BX Swiss:NNFN | BX Swiss | Switzerland | CHF |
| Dusseldorf:NNFN | Dusseldorf | Germany | EUR |
| Frankfurt:NNFN · This page | Frankfurt | Germany | EUR |
| Stuttgart:NNFN | Stuttgart | Germany | EUR |
Valuation
EV/sales 3.5× against a median of 90.4×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.46B USD
- P/E
- Loss
- EV/sales
- 3.5×
- EV/EBITDA
- 309×
- Price/book
- Negative equity
- Gross margin
- 76.0%
- Operating margin
- −2.9%
- Net margin
- −18.1%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.06
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MannKind Corporation · NASDAQ:MNKD | US$1.24B | US$1.46B | n/a | 3.5× | 309× | n/a | −18.1% | n/a | 1.06 |
| Absci Corporation · NASDAQ:ABSI | US$1.30B | US$1.13B | n/a | 758× | n/a | 5.9× | n/a | 0.0× | 3.20 |
| Avalyn Pharma Inc. · NASDAQ:AVLN | US$1.26B | US$946.4M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 0.12 |
| LB Pharmaceuticals Inc · NASDAQ:LBRX | US$1.26B | US$858.7M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 0.81 |
| Novavax, Inc. · NASDAQ:NVAX | US$1.23B | US$902.3M | n/a | 2.2× | n/a | n/a | −18.6% | n/a | 1.98 |
| Silence Therapeutics PLC · NASDAQ:SLN | US$1.23B | US$984.6M | n/a | 2,159× | n/a | 5.7× | n/a | 0.0× | 1.07 |
| Ocular Therapeutix, Inc. · NASDAQ:OCUL | US$1.23B | US$774.9M | n/a | 15.4× | n/a | 2.8× | −648.6% | 0.2× | 1.35 |
| Generate Biomedicines, Inc. · NASDAQ:GENB | US$1.22B | US$895.6M | n/a | 28.1× | n/a | 3.2× | −637.0% | 0.2× | 1.90 |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| Median of the others | US$1.23B | US$877.2M | 90.4× | 3.4× | −637.0% | 0.0× | 1.37 |
Forecasts
8 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.33 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.015 · 4 analysts
- Revenue, year to Dec 2026
- 434.6M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Castagna | Chief Executive Officer |
| Chris Prentiss | Chief Financial Officer |
| David Thomson | General Counsel and Corporate Secretary |
| Kate Miranda | Investor Relations |
| Sanjay Singh | Executive Vice President, Technical Operations MannKind |
| Ajay Ahuja | Chief Medical Officer |
| Alfred E. Mann | Founder |
| Stuart Tross | Chief People and Workplace Officer |
Board
| Director | Role |
|---|---|
| James Shannon | Chairman of the Board |
| Anthony Hooper | Audit Committee member, Compensation Committee Chair |
| Christine Mundkur | Audit Committee member, Nominating and Corporate Governance Committee member |
| Jennifer Grancio | Audit Committee member, Nominating and Corporate Governance Committee chair |
| Michael Castagna | Chief Executive Officer |
| Michael Friedman | Nominating and Corporate Governance Committee member |
| Ronald Consiglio | Audit Committee chair |
| Sabrina Kay | Audit Committee member, Compensation Committee member |
Events
Calls
| Call | When | Status |
|---|---|---|
| MannKind (NASDAQ:MNKD) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 4:30 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q1 2026 Earnings Call | Wed, May 06, 2026 · 4:30 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 9:00 AM ET | Replay |
| MannKind (NASDAQ:MNKD) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 9:00 AM ET | Replay |
| MannKind (NASDAQ:MNKD) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 9:00 AM ET | Replay |
| MannKind (NASDAQ:MNKD) Q1 2025 Earnings Call | Thu, May 08, 2025 · 9:00 AM ET | Replay |
| MannKind (NASDAQ:MNKD) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 4:30 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:30 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 9:00 AM ET | Replay |
All 21 calls
| Call | When | Status |
|---|---|---|
| MannKind (NASDAQ:MNKD) Q1 2024 Earnings Call | Wed, May 08, 2024 · 5:00 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q4 2023 Earnings Call | Tue, Feb 27, 2024 · 5:00 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q3 2023 Earnings Call | Tue, Nov 07, 2023 · 5:00 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q2 2023 Earnings Call | Mon, Aug 07, 2023 · 5:00 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q1 2023 Earnings Call | Tue, May 09, 2023 · 5:00 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q4 2022 Earnings Call | Thu, Feb 23, 2023 · 5:00 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q3 2022 Earnings Call | Tue, Nov 08, 2022 · 9:00 AM ET | Replay |
| MannKind (NASDAQ:MNKD) Q2 2022 Earnings Call | Tue, Aug 09, 2022 · 5:00 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q1 2022 Earnings Call | Thu, May 05, 2022 · 5:00 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q3 2021 Earnings Call | Tue, Nov 09, 2021 · 5:00 PM ET | Replay |
| MannKind (NASDAQ:MNKD) Q2 2021 Earnings Call | Wed, Aug 11, 2021 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +3.7% |
| Q2 2026 | Aug 5, 2026 · After close | −5.1% |
| Q1 2026 | May 7, 2026 | −1.1% |
| Q4 2025 | Feb 26, 2026 · Before open | −7.4% |
| Q3 2025 | Nov 5, 2025 · Before open | +10.6% |
| Q2 2025 | Aug 6, 2025 · Before open | −13.0% |
| Q1 2025 | May 6, 2025 · Before open | −3.6% |
| Q4 2024 | Feb 26, 2025 · After close | −4.4% |
| Q3 2024 | Nov 7, 2024 · After close | −0.5% |
| Q2 2024 | Aug 7, 2024 · Before open | −4.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −2.0% |
| Q4 2023 | Feb 27, 2024 · After close | +3.7% |
| Q3 2023 | Nov 7, 2023 · After close | −4.0% |
| Q2 2023 | Aug 7, 2023 · After close | +18.5% |
| Q1 2023 | May 9, 2023 · After close | +15.8% |
| Q4 2022 | Feb 22, 2023 · Before open | −1.5% |
| Q3 2022 | Nov 8, 2022 · Before open | +5.0% |
| Q2 2022 | Aug 9, 2022 · After close | +4.9% |
| Q1 2022 | May 5, 2022 · After close | −3.9% |
| Q4 2021 | Feb 24, 2022 · After close | −6.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 36 slides | Aug 5, 2026 |
| Investor Presentation (August 2026) | Investor deck | 34 slides | August 2026 |
| Technical Presentation (July 2026) | Technical | 34 slides | Jul 29, 2026 |
| Corporate Update (July 2026) | Corporate update | 23 slides | Jul 24, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 31 slides | Feb 26, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 34 slides | Nov 5, 2025 |
| Merger or Acquisition (August 2025) | Merger or acquisition | 15 slides | Aug 25, 2025 |
| J.P. Morgan Healthcare Conference 2016 | Conference | 14 slides | Jan 13, 2016 |
| Fact Sheet (June 2011) | Fact sheet | 2 slides | June 2011 |
Financings
| Raise | Date |
|---|---|
| Private placement of unstated Closed: US$50M raised · US$3.89 a share Buyers: Frazier Life Sciences Use of proceeds: To fund the $45 million CVR payment triggered by the FDA approval of Furoscix ReadyFlow | Aug 5, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 349.0M | 285.5M | 199.0M | 99.8M | 75.4M | 65.1M | 63.0M | 27.9M | 11.7M | 174.8M |
| Cost of revenue | 26.8M | 17.4M | 20.9M | 16.0M | 16.8M | 15.1M | 20.1M | 19.4M | 17.2M | 17.1M |
| Gross profit | 287.8M | 208.9M | 136.2M | 42.3M | 36.6M | 40.5M | 35.1M | 7.38M | -5.48M | 124.7M |
| Research and development | 66.3M | 45.9M | 31.3M | 19.7M | 12.3M | 6.25M | 6.90M | 8.74M | 14.1M | 14.9M |
| Selling, general and administrative | 144.1M | 94.3M | 94.3M | 91.5M | 77.4M | 59.0M | 74.7M | 79.7M | 75.0M | 46.9M |
| Operating income | 38.8M | 72.6M | 8.68M | -64.1M | -47.0M | -47.9M | -44.6M | -76.6M | -108.2M | 67.3M |
| Depreciation and amortization | 12.3M | 7.37M | 4.54M | 3.33M | 1.99M | 2.15M | 972.0K | 2.86M | 1.80M | 2.40M |
| EBITDA | 51.1M | 80.0M | 13.2M | -60.8M | -45.0M | -45.8M | -43.6M | -73.7M | -106.4M | 69.7M |
| Interest expense | 13.8M | 12.0M | 15.2M | 15.0M | 15.2M | 9.47M | 6.30M | 5.12M | 9.49M | 15.6M |
| Income before tax | 1.41M | 30.5M | -10.4M | -87.4M | -80.9M | -57.5M | -51.9M | -86.7M | -117.3M | 125.7M |
| Income tax | -4.46M | 2.93M | 1.56M | 0 | 0 | -218.0K | 0 | 240.0K | 51.0K | 0 |
| Net income | 5.86M | 27.6M | -11.9M | -87.4M | -80.9M | -57.2M | -51.9M | -87.0M | -117.3M | 125.7M |
| Earnings per share, basic | 0.02 | 0.10 | -0.04 | -0.34 | -0.32 | -0.26 | -0.27 | -0.60 | -1.13 | 1.37 |
| Earnings per share, diluted | 0.02 | 0.10 | -0.04 | -0.34 | -0.32 | -0.26 | -0.27 | -0.60 | -1.13 | 1.36 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 74.9M | 46.3M | 238.5M | 69.8M | 124.2M | 67.0M | 29.9M | 71.2M | 43.9M | 22.9M |
| Short-term investments | 96.5M | 150.9M | 56.6M | 101.1M | 79.9M | 0 | 20.0M | 4.81M | 350.0K | |
| Receivables | 38.4M | 11.8M | 14.9M | 16.8M | 4.74M | 4.22M | 3.51M | 4.02M | 2.79M | 302.0K |
| Inventory | 35.3M | 27.9M | 28.5M | 21.8M | 7.15M | 4.97M | 4.16M | 3.60M | 2.66M | 2.33M |
| Current assets | 291.6M | 268.3M | 373.4M | 234.9M | 219.5M | 79.5M | 60.8M | 81.9M | 57.2M | 77.5M |
| Property, plant and equipment | 82.4M | 85.4M | 84.2M | 45.1M | 36.6M | 25.9M | 26.8M | 25.6M | 26.9M | 28.9M |
| Goodwill | 67.6M | 1.93M | 1.93M | 2.43M | 0 | 0 | 0 | |||
| Total assets | 792.2M | 393.8M | 475.2M | 295.3M | 321.2M | 108.6M | 93.7M | 107.7M | 84.6M | 107.1M |
| Accounts payable | 9.03M | 6.79M | 9.58M | 11.1M | 6.96M | 5.58M | 4.79M | 5.38M | 6.98M | 3.26M |
| Current liabilities | 171.0M | 81.8M | 104.1M | 67.3M | 48.3M | 73.7M | 65.6M | 75.2M | 87.6M | 92.1M |
| Long-term debt | 318.4M | 36.1M | 248.7M | 368.0M | 223.9M | 5.00M | 113.9M | 91.2M | 104.1M | 77.2M |
| Total debt | 354.6M | 36.1M | 268.7M | 273.5M | 281.2M | 122.2M | 118.9M | 102.5M | 156.8M | 148.5M |
| Total liabilities | 843.2M | 472.7M | 721.4M | 545.8M | 530.5M | 289.0M | 284.3M | 282.8M | 299.3M | 290.7M |
| Shareholders' equity | -51.0M | -78.8M | -246.2M | -250.5M | -209.3M | -180.4M | -190.5M | -175.1M | -214.7M | -183.6M |
| Shares outstanding | 307.8M | 303.0M | 270.0M | 263.8M | 251.5M | 242.1M | 211.8M | 187.0M | 119.1M | 95.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 18.3M | 42.5M | 34.1M | -80.7M | -61.7M | -28.1M | -88.5M | -37.7M | -64.8M | -78.1M |
| Capital spending | -4.57M | -9.69M | -42.4M | -7.59M | -11.5M | -801.0K | -2.56M | -354.0K | -1.14M | -1.14M |
| Free cash flow | 13.7M | 32.8M | -8.35M | -88.3M | -73.2M | -28.9M | -91.0M | -38.1M | -64.8M | -79.2M |
| Cash from investing | -304.8M | -96.6M | -1.99M | 4.87M | -151.5M | 15.2M | -22.8M | -234.0K | 16.7M | -1.13M |
| Cash from financing | 315.1M | -137.3M | 136.6M | 21.4M | 270.3M | 49.9M | 69.9M | 61.3M | 73.6M | 43.0M |
| Dividends paid | -498.0K | -14.9M | -656.0K | 0 | 0 | |||||
| Share buybacks | -3.26M | -10.2M | 19.4M | -498.0K | 684.0K | 656.0K | 67.9M | -127.0K | -165.0K | |
| Change in cash | 28.6M | -191.4M | 168.7M | -54.4M | 57.0M | 36.9M | -41.5M | 23.3M | 25.5M | -36.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| 424B7 · Prospectus | Aug 21, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 24, 2026 | Financing | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 17, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 2, 2026 | Current report | SEC |
| 8-K · Current report | May 28, 2026 | Current report | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 8-K · Current report | May 22, 2026 | Meeting outcome | SEC |
| 144/A · Notice of proposed sale, amended | May 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | May 8, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 7, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 7, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 7, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Dec 15, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 9, 2025 | Acquisition or disposal | SEC |
| SC TO-T/A | Oct 7, 2025 | Acquisition or disposal | SEC |
| SC TO-T/A | Sep 30, 2025 | Acquisition or disposal | SEC |
| SC TO-T/A | Sep 29, 2025 | Acquisition or disposal | SEC |
| SC TO-T/A | Sep 24, 2025 | Acquisition or disposal | SEC |
| SC TO-T/A | Sep 22, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 16, 2025 | Other filings | SEC |
| SC TO-T | Sep 8, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Aug 27, 2025 | Material contract | SEC |
| SC TO-C | Aug 25, 2025 | Other filings | SEC |
| SC TO-C | Aug 25, 2025 | Other filings | SEC |
| SC TO-C | Aug 25, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 25, 2025 | Material contract | SEC |
| 4 · Change in ownership | Aug 6, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | Jul 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 16, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 14, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jun 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| 8-K · Current report | May 19, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | May 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 8-K · Current report | May 15, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | May 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 13, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 1, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 1, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 28, 2025 | Insider trade | SEC |
| S-3ASR · Registration statement | Feb 26, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 6, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 18, 2024 | Financing | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 22, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 144 · Notice of proposed sale | Nov 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 14, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 16, 2024 | Other filings | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from MannKind Corporation’s releases · as of Oct 23, 2026
- Common shares
- 321,640,118
- Fully diluted
- 321,640,118
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 321,640,118 | Oct 23, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 23, 2026 | 321,640,118 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James Shannon Other companies: ProQR Therapeutics N.V. (Director · Since at least Mar 18, 2026); Xilio Therapeutics, Inc. (Board Member · Since at least Jun 13, 2024); Horizon Pharma PLC (Director · Aug 2, 2017 – Aug 2, 2018 · Past); Endocyte Inc (Director · Feb 4, 2011 – May 26, 2011 · Past) | Chairman of the Board · Since at least Jun 10, 2010 |
| Kent Kresa Other companies: NuScale Power Corporation (Director · Since at least May 2, 2022); Avery Dennison Corporation (Director · Mar 31, 2006 – Apr 22, 2010 · Past); General Motors Company (Director · Dec 31, 2005 – Jun 7, 2010 · Past); Fluor Corporation (Director · Dec 30, 2005 – Apr 29, 2014 · Past) | Director · May 25, 2006 – May 15, 2024 · Past |
| Anthony Hooper Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Jun 11, 2026); Amgen Inc. (EVP, Global Commercial Ops. · Oct 27, 2011 – May 3, 2018 · Past); Bristol-Myers Squibb Company (SVP ComOps Pres USJap Int · May 3, 2010 – May 13, 2011 · Past) | Audit Committee member, Compensation Committee Chair · Since at least Jan 1, 2020 |
| Burkhard Blank Other companies: Acorda Therapeutics Inc (CMO and Head of R&D · Jul 1, 2016 – Mar 3, 2021 · Past) | EVP Chief Medical Officer · Since at least May 24, 2023 |
| Christine Mundkur Other companies: Cardinal Health, Inc. (Director · Since at least Sep 6, 2022) | Audit Committee member, Nominating and Corporate Governance Committee member · Since at least Feb 20, 2019 |
| Richard L Anderson Other companies: Via Pharmaceuticals Inc (Director · Dec 17, 2008 – Dec 17, 2008 · Past) | Corporate VP · Sep 26, 2008 – Sep 26, 2008 · Past |
| Stuart Tross Other companies: Amgen Inc. (SVP, Human Resources · Oct 21, 2013 – May 3, 2016 · Past) | Chief People and Workplace Officer · Since at least Dec 23, 2016 |
| Ajay Ahuja | Chief Medical Officer · Since at least Sep 29, 2025 |
| Alejandro Galindo | EVP Endocrine Business Unit · Dec 8, 2020 – Aug 22, 2022 · Past |
| Alfred E. Mann | Founder · Since at least Nov 6, 2025 |
All 24 people
| Person | Seat |
|---|---|
| Chris Prentiss | Chief Financial Officer · Since at least Mar 4, 2026 |
| David M Kendall | Chief Medical Officer · Feb 12, 2018 – Jul 31, 2020 · Past |
| David Thomson | EVP Genl Counsel & Secretary · Since at least May 16, 2018 |
| Jennifer Grancio | Audit Committee member, Nominating and Corporate Governance Committee chair · Since at least Mar 23, 2020 |
| Joseph Kocinsky | Chief Technology Officer · May 16, 2018 – Aug 27, 2022 · Past |
| Kate Miranda | Investor Relations · Since at least Oct 9, 2026 |
| Lauren M Sabella | EVP Operations · Since at least Dec 31, 2023 |
| Linda A Adreveno | Sr. VP, HR · Feb 18, 2016 – Feb 18, 2016 · Past |
| Michael Castagna | Chief Executive Officer, Director · Since at least May 11, 2026 |
| Michael Friedman | Director · Since at least May 10, 2022 |
| Ronald Consiglio | Audit Committee chair · Since at least May 14, 2019 |
| Sabrina Kay | Audit Committee member, Compensation Committee member · Since at least Nov 5, 2026 |
| Sanjay Singh | Executive Vice President, Technical Operations MannKind · Since at least Oct 31, 2022 |
| Steven B Binder | Director · Since at least Jul 25, 2017 |
Log in to ask 6ix AI your own questions about MannKind Corporation.